Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04084483 · ClinicalTrials.gov registry record · Phase 2
A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease
A Phase 2 study, sponsored by Kowa Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 238
- Enrollment target
NCT04084483 is a Phase 2 study that has completed, run by Kowa Research Institute. The registered enrollment target is 238 participants.
The verdict
NCT04084483, a Phase 2 study, has completed, sponsored by Kowa Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 238 participants
- Enrollment target
Study Summary
The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
Interventions
- DRUG K-161
- OTHER Placebo (Vehicle)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2019-08-04 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04084483
The ClinicalTrials.gov registry entry for NCT04084483 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kowa Research Institute, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which K-161 is the first listed.
NCT04084483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04084483 about?
NCT04084483 is a clinical study titled "A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease". The objective of the study is to assess the safety, efficacy, optimum dosage, and dosing regimen of K-161 in adult subjects with moderate to severe dry eye disease.
What is the current status of trial NCT04084483?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 238 participants. The study started on 2019-08-04. Estimated completion is 2020-01-09.
What interventions are being tested in trial NCT04084483?
The interventions under investigation include: K-161 (DRUG), Placebo (Vehicle) (OTHER).
Who is sponsoring clinical trial NCT04084483?
This trial is sponsored by Kowa Research Institute, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.